Mathematical Modelling of the Immunotherapies in Hematologic Malignancies
Institute of Mathematics and Informatics – Bulgarian Academy of Sciences (IMI BAS), Bulgaria
Peter Rashkov
Find out moreIndividual
DC projects
Defining the Mechanistic Impact of PTPN11 Mutations on Leukemic Transformation and Disease Progression in Juvenile Myelomonocytic Leukemia
University of Milano-Bicocca (UNIMIB), Italy
Emanuele Azzoni
Find out more
Investigating Mechanisms of Brain Infiltration and Chemotherapy Resistance in T-cell Acute Lymphoblastic Leukemia
Université Paris Cité (UPCité), France
Diana Passaro
Find out more
Determining the Long-lasting Impact of T-cell Leukemia and Lymphoma on Hematopoietic niches
nstitute for Research and Innovation in Health – University of Porto (i3S), Portugal
Nuno R. dos Santos
Find out more
Identifying Rational Approaches to Enhance the Activity of the Anti-cancer Drug Venetoclax
Stichting Amsterdam University Medical Center (AUMC), Netherlands
Rachel Thijssen
Find out more
Mechanisms of Resistance to MEK Inhibitors in Leukemia and Identification of Targeted Therapeutic Approaches
Josep Carreras Leukemia Research Institute (IJC), Spain
Laura Belver
Find out more
Enhancing CAR-NK Cell Therapies to Target Acute Myeloid Leukemia and Overcome Immune Resistance
Eberhard Karls University of Tübingen (UT), Germany
Claudia Lengerke
Find out more
Prevent Progression of Myelofibrosis to Acute Myeloid Leukemia
Karolinska Institute (KI), Sweden
Andreas Lennartsson
Find out more
Characterization of AID-dependent Mutations on MicroRNA Function
Complutense University of Madrid (UCM), Spain
Virginia G. de Yébenes
Find out more
AI-driven Proteoform-based Drug Repurposing for Targeted Cancer Therapies
National Hellenic Research Foundation (NHRF), Greece
Theodora Katsila
Find out more
RNA Methylation Gain as a Mechanism of Resistance to Therapy in Myelodysplastic Syndromes
Iuliu Haţieganu University of Medicine and Pharmacy (UMF Cluj), Romania
Ciprian Tomuleasa
Find out more
Optimization and Preclinical Evaluation of Novel SHP2 inhibitors
Josep Carreras Leukemia Research Institute (IJC, Spain
Laura Belver
Find out more
CAR-T cell Double Targeting Strategies to Overcome Tumor Antigen Escape and Microenvironment Inhibition
OneChain Immunotherapeutics (OneChain), Spain
Víctor M. Díaz
Find out more
Development of Therapeutic Antibodies for Treating Acute Myeloid Leukemia
Lead Biologics (Lead), Sweden
Anki Malmborg Hager
Find out more
Novel preclinically-validated GATA3 inhibitor/degrader as a therapy for T-cell Acute Lymphoblastic Leukemia
Faculty of Pharmacy – University of Belgrade (FPHUB), Serbia
Katarina Nikolić
Find out more
Targeting Metabolic Pathways in Leukemic Stem Cells for AML Treatment
ETH Zürich, Switzerland
Nina Cabezas-Wallscheid
Find out more